These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16497612)

  • 1. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects.
    Wilder-Smith CH; Jonzon B; Fornstedt-Wallin B; Hedman A; Karlsson P
    Scand J Gastroenterol; 2006 Mar; 41(3):264-73. PubMed ID: 16497612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
    Lohmander LS; McKeith D; Svensson O; Malmenäs M; Bolin L; Kalla A; Genti G; Szechinski J; Ramos-Remus C;
    Ann Rheum Dis; 2005 Mar; 64(3):449-56. PubMed ID: 15345500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.
    Hawkey CJ; Jones JI; Atherton CT; Skelly MM; Bebb JR; Fagerholm U; Jonzon B; Karlsson P; Bjarnason IT
    Gut; 2003 Nov; 52(11):1537-42. PubMed ID: 14570719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582.
    Fagerholm U; Björnsson MA
    J Pharm Pharmacol; 2005 Dec; 57(12):1539-54. PubMed ID: 16354398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years.
    Goldstein JL; Aisenberg J; Lanza F; Schwartz H; Sands GH; Berger MF; Pan S
    Clin Ther; 2006 Mar; 28(3):340-51. PubMed ID: 16750449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A
    Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.
    Moberly JB; Harris SI; Riff DS; Dale JC; Breese T; McLaughlin P; Lawson J; Wan Y; Xu J; Truitt KE
    Dig Dis Sci; 2007 Feb; 52(2):442-50. PubMed ID: 17216336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients.
    Bianchi Porro G; Lazzaroni M; Petrillo M
    Am J Gastroenterol; 1997 Apr; 92(4):663-7. PubMed ID: 9128319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects.
    Stoltz RR; Harris SI; Kuss ME; LeComte D; Talwalker S; Dhadda S; Hubbard RC
    Am J Gastroenterol; 2002 Jan; 97(1):65-71. PubMed ID: 11808971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin.
    Schiff M; Hochberg MC; Oldenhof J; Brune K
    Curr Med Res Opin; 2009 Oct; 25(10):2471-7. PubMed ID: 19678751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods.
    Young DV; Cochran ED; Dhawan V; Earl RA; Ellis JL; Garvey DS; Janero DR; Khanapure SP; Letts LG; Melim TL; Murty MG; Shumway MJ; Wey SJ; Zemtseva IS; Selig WM
    Biochem Pharmacol; 2005 Nov; 70(9):1343-51. PubMed ID: 16168964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study.
    Fiorucci S; Santucci L; Gresele P; Faccino RM; Del Soldato P; Morelli A
    Gastroenterology; 2003 Mar; 124(3):600-7. PubMed ID: 12612897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
    Bias P; Buchner A; Klesser B; Laufer S
    Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen.
    Lanza FL; Codispoti JR; Nelson EB
    Am J Gastroenterol; 1998 Jul; 93(7):1051-4. PubMed ID: 9672328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.